DIRECT

Disabling Radiotherapy resistance in Cancer Treatment

Coordinatore	UNIVERSITEIT MAASTRICHT    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	1˙830˙510 €
EC contributo	1˙830˙510 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-CoG
Funding Scheme	ERC-CG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-05-01   -   2019-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF AUCKLAND  Organization address address: PRINCES STREET 24 city: AUCKLAND postcode: 1142 contact info Titolo: Ms. Nome: Julia Cognome: Zhu Email: send email Telefono: 649374000000000	NZ (AUCKLAND)	beneficiary	288˙733.20
2	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Ms. Nome: Judith Cognome: Doomen Email: send email Telefono: +31 433881867 Fax: +31 433881890	NL (MAASTRICHT)	hostInstitution	1˙541˙776.80
3	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Prof. Nome: Marc Antoine Gijsbert Gilles Cognome: Vooijs Email: send email Telefono: +31 43 38882912 Fax: +31 43 388 4540	NL (MAASTRICHT)	hostInstitution	1˙541˙776.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cancer is a devastating disease affecting 1 in 3 people in their lifetime. The incidence is rising because of our aging population and causes a huge economic impact on our society because of hospitalization and lost productivity. Radiotherapy alone or in combination with surgery and/or chemotherapy is used in ~50% of all patients and uses ionizing radiation to induce DNA breaks that are lethal to cells. While significant progress has been made, radiotherapy is often limited because of side-effects in normal tissues and tumor control often fails because of resistance and metastases. Novel treatment paradigms are urgently needed. Among the key classical biological factors that determine radiation response in normal and tumor cells are the 4R; Reoxygenation, Repopulation, Redistribution and Repair. They are determined by intrinsic (genetic) as well as extrinsic factors from the tumor microenvironment and underlie tumor heterogeneity a hallmark of cancers and a decisive factor in clinical response. Yet, standard cancer treatments are largely based on the flawed assumption that tumors are homogenous within and between patients. We hypothesized that NOTCH signaling and tumor hypoxia cause tumor heterogeneity and are tumor selective therapeutic targets. First we will study key biological mechanisms that determine intra tumor heterogeneity, second we will establish their role in therapy response and third we will exploit this knowledge to enhance radiotherapy and provide proof of concept of a highly innovative approach to selectively activate cancer therapeutics targeting the NOTCH stem cell pathway in therapy resistant tumor cells without adverse effects in normal tissues. DIRECT interrogates the molecular details of key cancer therapy response parameters providing opportunities for the next generation of tumor cell specific treatments that improve disease outcome.'